Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. (NASDAQ: ASRT) generates a steady flow of news related to its role as a pharmaceutical company focused on oncology, neurology, and pain management. This news page aggregates company-issued press releases and other coverage so readers can follow developments that affect Assertio’s business and ASRT stock.
Recent communications emphasize Assertio’s commercial execution around Rolvedon, a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in certain adult cancer patients, and SYMPAZAN, an oral film formulation of clobazam approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. News items include clinical trial readouts, such as a phase 1 study of same-day dosing of Rolvedon with chemotherapy, and real-world evidence studies describing how Sympazan is used in daily clinical practice.
Investors and observers will also find updates on financial results, guidance ranges, and strategic priorities, including portfolio focus on core growth assets, responses to generic competition for products like Indocin, and steps to streamline the corporate structure. Assertio’s announcements cover quarterly net product sales, adjusted EBITDA, and commentary on commercial performance, alongside information about investor conference participation and earnings calls.
Governance and capital markets developments appear in the news flow as well, such as leadership transitions at the chief executive level, the appointment of a President and Chief Operating Officer, and the implementation of a 1-for-15 reverse stock split to support Nasdaq listing compliance. Subsequent confirmation from Nasdaq that Assertio regained compliance with listing requirements is also communicated through press releases.
By reviewing the ASRT news feed, readers can track clinical data publications, operational updates, executive changes, supply and licensing agreements, and listing status disclosures that help explain how Assertio is executing its stated strategy in oncology, neurology, and pain management.
Assertio Holdings (NASDAQ: ASRT) announced its participation in the LD Micro Invitational XII Conference from June 7-9, 2022 at the Four Seasons Hotel in Westlake Village, CA. The Company will present on June 8, 2022, at 3:00 PM PT in Track 1, with opportunities for 1:1 meetings with investors throughout the day. Presentation information will be available on the event day at assertiotx.com. Investors can contact LD Micro or Matt Kreps from Darrow Associates for meeting inquiries.
Assertio Holdings, Inc. (ASRT) reported strong financial results for Q1 2022, with net product sales rising 37% year-over-year to $35.5 million. Net income reached $9.1 million, up 99% from the previous year, driven by higher sales and improved gross profit margin of 88%. The company also raised its full-year non-GAAP adjusted EBITDA guidance to $66-$74 million, reinforcing its commitment to growth and a goal of adding $40 million in gross profit by 2024.
Assertio Holdings, Inc. (NASDAQ: ASRT) is set to release its first quarter 2022 financial results on May 9, 2022, after market close. A live webcast of the earnings conference call will follow at 4:30 p.m. ET. Investors can access the webcast and related materials through the company's investor relations website. Assertio focuses on specialty pharmaceuticals, leveraging a non-personal promotional model while expanding its product portfolio through both existing and new opportunities.
Assertio Holdings, Inc. (NASDAQ: ASRT) and BlinkRx have announced a collaboration aimed at facilitating patient access to Otrexup, a once-weekly auto-injector that delivers methotrexate. This partnership seeks to eliminate barriers to medication access for patients and healthcare professionals. The BlinkRx program provides patients with transparent pricing, free home delivery, and personalized support. Assertio's CEO, Dan Peisert, expressed enthusiasm for this digital solution, aligning with the company's strategy for enhanced patient engagement.
Assertio Holdings, Inc. (ASRT) reported a 7% increase in fourth quarter net product sales to $32.2 million and $109.4 million for the full year 2021, driven by price favorability for Cambia and Indocin. The non-GAAP adjusted EBITDA surged 118% year-over-year to $17.8 million in Q4. The company provided 2022 guidance for net product sales between $126 million and $136 million and adjusted EBITDA from $64 million to $72 million. Assertio completed the acquisition of Otrexup, contributing to its growth strategy.
Assertio Holdings (NASDAQ: ASRT) will release its fourth quarter and full year 2021 financial results on March 9, 2022, before markets open. A live webcast of the earnings conference call is scheduled for 9:00 AM ET the same day. Investors can access details via the investor relations website. Assertio focuses on creating a differentiated pharmaceutical portfolio through product innovation and acquisitions.
Assertio Holdings (NASDAQ: ASRT) announced participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. CEO Dan Peisert and CFO Paul Schwichtenberg will represent the company. An investor presentation is now available for on-demand viewing on the Assertio Investor Relations website for 30 days. Assertio focuses on commercializing differentiated pharmaceutical products in neurology, hospital care, and pain management. For more details, visit Assertio's website.
Assertio Holdings, Inc. (Nasdaq: ASRT) has announced the acquisition of Otrexup (methotrexate) from Antares Pharma for a total of $44 million, including $18 million paid upfront. This acquisition, the first since 2015, aims to enhance Assertio's growth and leverage its digital platform for commercialization. Assertio raised its full-year net product sales guidance to over $108 million and adjusted EBITDA to over $48 million for 2021, fueled by strong existing product sales and expected contributions from Otrexup.
Assertio Holdings, Inc. (ASRT) announced a preliminary settlement agreement regarding three shareholder derivative lawsuits against its subsidiary, Assertio Therapeutics, approved by the California Superior Court. The lawsuits, alleging breaches of fiduciary duties among other claims, will lead to corporate governance changes lasting at least two years. Assertio will also pay $150,000 in legal fees, subject to court approval. A settlement hearing is scheduled for December 14, 2021, to finalize the agreement and address any objections from current stockholders.
Assertio, a pharmaceutical company, reported Q3 2021 financial results, achieving net product sales of $25.997 million and a net income of $3.737 million. This marks a significant improvement from a net loss of $10.522 million in Q3 2020. The company raised its full-year net product sales guidance to over $103 million and adjusted EBITDA guidance to exceed $43 million. Sequentially, Assertio generated $4.7 million in operating cash flows, its highest since Q4 2019, while settling legal uncertainties, including a $7 million antitrust litigation settlement.